The post 2 Nvidia stock killers to watch in 2026 appeared on BitcoinEthereumNews.com. In recent years, American semiconductor giant Nvidia (NASDAQ: NVDA) has been synonymous with the AI revolution, with its GPUs forming the backbone of the sector. Notably, the company’s dominance has been fueled by advanced hardware, a robust software ecosystem, and strong relationships with major technology players. Meanwhile, as AI adoption accelerates and the market for specialized chips grows, new competitors are emerging, each aiming to challenge Nvidia’s hegemony in both data-center and AI infrastructure markets.  To this end, below are two stocks to watch for 2026, as they stand a strong chance of challenging Nvidia’s dominance. Advanced Micro Devices (NASDAQ: AMD) Among the companies looking to make significant inroads by 2026, Advanced Micro Devices (NASDAQ: AMD) is perhaps the most formidable, having shown signs of competing with Nvidia chips. AMD’s Instinct MI-series GPUs, including the MI300X and MI350, are increasingly capable of rivaling Nvidia’s high-end offerings in large-scale AI training. These GPUs deliver compelling performance-per-dollar value, an attribute that has caught the attention of major AI developers and cloud providers seeking to optimize costs without compromising efficiency. AMD has also secured critical design wins with major AI players such as OpenAI, signaling that its chips are not only theoretically competitive but are being adopted in real-world deployments. Beyond hardware, AMD has invested heavily in its ROCm software stack, narrowing the gap with Nvidia’s ecosystem and making it easier for developers to migrate workloads. These developments have positioned AMD as a serious contender for capturing a growing share of the AI GPU market. By press time, AMD stock was trading at $217.43, having rallied 80% year to date. AMD YTD stock price chart. Source: Finbold Qualcomm (NASDAQ: QCOM) Qualcomm (NASDAQ: QCOM), meanwhile, is carving a niche in the AI data-center space with its AI200 and AI250 chips, designed specifically for inference… The post 2 Nvidia stock killers to watch in 2026 appeared on BitcoinEthereumNews.com. In recent years, American semiconductor giant Nvidia (NASDAQ: NVDA) has been synonymous with the AI revolution, with its GPUs forming the backbone of the sector. Notably, the company’s dominance has been fueled by advanced hardware, a robust software ecosystem, and strong relationships with major technology players. Meanwhile, as AI adoption accelerates and the market for specialized chips grows, new competitors are emerging, each aiming to challenge Nvidia’s hegemony in both data-center and AI infrastructure markets.  To this end, below are two stocks to watch for 2026, as they stand a strong chance of challenging Nvidia’s dominance. Advanced Micro Devices (NASDAQ: AMD) Among the companies looking to make significant inroads by 2026, Advanced Micro Devices (NASDAQ: AMD) is perhaps the most formidable, having shown signs of competing with Nvidia chips. AMD’s Instinct MI-series GPUs, including the MI300X and MI350, are increasingly capable of rivaling Nvidia’s high-end offerings in large-scale AI training. These GPUs deliver compelling performance-per-dollar value, an attribute that has caught the attention of major AI developers and cloud providers seeking to optimize costs without compromising efficiency. AMD has also secured critical design wins with major AI players such as OpenAI, signaling that its chips are not only theoretically competitive but are being adopted in real-world deployments. Beyond hardware, AMD has invested heavily in its ROCm software stack, narrowing the gap with Nvidia’s ecosystem and making it easier for developers to migrate workloads. These developments have positioned AMD as a serious contender for capturing a growing share of the AI GPU market. By press time, AMD stock was trading at $217.43, having rallied 80% year to date. AMD YTD stock price chart. Source: Finbold Qualcomm (NASDAQ: QCOM) Qualcomm (NASDAQ: QCOM), meanwhile, is carving a niche in the AI data-center space with its AI200 and AI250 chips, designed specifically for inference…

2 Nvidia stock killers to watch in 2026

In recent years, American semiconductor giant Nvidia (NASDAQ: NVDA) has been synonymous with the AI revolution, with its GPUs forming the backbone of the sector.

Notably, the company’s dominance has been fueled by advanced hardware, a robust software ecosystem, and strong relationships with major technology players.

Meanwhile, as AI adoption accelerates and the market for specialized chips grows, new competitors are emerging, each aiming to challenge Nvidia’s hegemony in both data-center and AI infrastructure markets. 

To this end, below are two stocks to watch for 2026, as they stand a strong chance of challenging Nvidia’s dominance.

Advanced Micro Devices (NASDAQ: AMD)

Among the companies looking to make significant inroads by 2026, Advanced Micro Devices (NASDAQ: AMD) is perhaps the most formidable, having shown signs of competing with Nvidia chips.

AMD’s Instinct MI-series GPUs, including the MI300X and MI350, are increasingly capable of rivaling Nvidia’s high-end offerings in large-scale AI training. These GPUs deliver compelling performance-per-dollar value, an attribute that has caught the attention of major AI developers and cloud providers seeking to optimize costs without compromising efficiency.

AMD has also secured critical design wins with major AI players such as OpenAI, signaling that its chips are not only theoretically competitive but are being adopted in real-world deployments.

Beyond hardware, AMD has invested heavily in its ROCm software stack, narrowing the gap with Nvidia’s ecosystem and making it easier for developers to migrate workloads.

These developments have positioned AMD as a serious contender for capturing a growing share of the AI GPU market.

By press time, AMD stock was trading at $217.43, having rallied 80% year to date.

AMD YTD stock price chart. Source: Finbold

Qualcomm (NASDAQ: QCOM)

Qualcomm (NASDAQ: QCOM), meanwhile, is carving a niche in the AI data-center space with its AI200 and AI250 chips, designed specifically for inference workloads.

While Nvidia dominates high-end training, inference is a rapidly expanding segment where memory bandwidth and energy efficiency are critical. Qualcomm’s chips promise higher memory throughput and lower power consumption, translating into significant cost savings for organizations running large-scale AI inference operations.

Early reports indicate that several data-center operators plan to deploy Qualcomm’s solutions, demonstrating initial commercial traction and validating their efficiency-focused approach.

At the close of the last market session, QCOM stock was trading at $168, up almost 10% year to date.

QCOM YTD stock price chart. Source: Finbold

While Nvidia’s dominance is far from over, these emerging competitors illustrate a market in transition. They have the potential to take over, provided the AI market remains strong and they continue to deliver on their growth projections.

Featured image via Shutterstock

Source: https://finbold.com/2-nvidia-stock-killers-to-watch-in-2026/

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26